Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 70

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 70
---
553 $13,151 Stock-based compensation from:    Stock options$4,440 $6,729     Restricted stock units9,606 6,210     Employee stock purchase plan share options507 212         Total$14,553 $13,151 

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 26

Equity AwardsThe following tables contain information about the Company’s stock option and restricted stock unit, or RSU, activity for the three months ended March 31, 2025:Stock Options Number ofStock Options Weighted Average Exercise Price (Per Share) Outstanding at December 31, 20246,845,618 $42.95      Granted252,300 25.65      Forfeited(10,485)29.08      Expired(253,556)45.57  Outstanding at March 31, 20256,833,877 42.23 Restricted Stock Units Number ofRestrictedStock Units Weighted Average Grant Date Fair Value (Per Share)Unvested at December 31, 20242,769,728 $32.07      Granted2,177,261 26.19      Vested(52,708)40.80      Forfeited(52,862)27.79 Unvested at March 31, 20254,841,419 29.37 The weighted average fair value of stock options granted during the three months ended March 31, 2025 was $13.88 per share. The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:Black-Scholes Weighted Average AssumptionThree Months Ended March 31, 2025Expected dividend yieldNoneRisk-free interest rate4.29%Expected volatility57.3%Expected term of options5.13 yearsEmployee Stock Purchase PlanThe Company’s Amended and Restated 2014 Employee Stock Purchase Plan, or ESPP, features two six-month offering periods per year, running from January 1 to June 30 and July 1 to December 31. Under the ESPP, employees may elect to contribute after-tax earnings to purchase shares at 85% of the closing fair market value of the Company’s common stock on either the offering date or